EGFR (HER1), epidermal growth factor receptor, is a tyrosine kinase receptor, which activates RAS/RAF/MEK and PI3K/AKT/mTOR pathways, leading to increased cell proliferation and growth. EGFR G721S lies within the protein kinase domain of the EGFR protein. G721S has been identified in the scientific literature in lung cancer, but has not been biochemically characterized and therefore, its effect on EGFR protein function is unknown. EGFR mutations are rare and in prostate adenocarcinoma and are identified in only about 1% of cases. The clinicopathologic significance of the EGFR G721S variant in prostate cancer remains to be fully elucidated.
Ichihara S et al. The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int J Cancer. 2007 Mar 15;120(6):1239-47.
Tanaka Y et al. Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer. Cancer Biol Ther. 2011 Jan 1;11(1):50-7. Cancer Genome Atlas Research Network. The Molecular Taxonomy of Primary Prostate Cancer. Cell. 2015 Nov 5;163(4):1011-25.
Disclaimer: You assume full responsibility for all risks associated with using this PMKB website. The IPM makes no guarantee of the comprehensiveness, reliability or accuracy of the information on this website and the IPM assumes no responsibility for errors in the information associated with this web site. Healthcare providers and patients must integrate all clinical and laboratory findings as well as information from a variety of sources before deciding on appropriate clinical care options.